Analysis of the Tumor Immunotherapy Gene Expression Resource further showed that melanoma patients with high SPOP expression had poorer responses to anti–PD-1 therapy (Figure 13D), likely due to reduced STING levels and lower tumor-infiltrating immune cells. This evidence concerns the gene SPOP and melanoma.